Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $34M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 27.02.2023 | Evolutiona... | evolutiona... |
| - | BoxGroup | boxgroup.c... |
| - | Tencent | tenx.tc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.01.2023 | Series A | $9M | 8VC |
| 30.07.2020 | Series A | $25M | - |
Mentions in press and media 6
| Date | Title | Description |
| 06.01.2023 | USA-based Mantra Bio raises USD 9 million in Series A-2 financing | San Francisco, California, USA-based developer of targeted therapeutics based on its engineering platform, Mantra Bio, raised USD 9 million in recent financing. The Series A-2 round took place on January 4, 2022. Samsung Securities joined i... |
| 05.01.2023 | Mantra Bio Raises $9M in Series A-2 Financing | Mantra Bio, a San Francisco, CA-based developer of targeted therapeutics based on its engineering platform, raised $9M in Series A-2M funding. New investor, Samsung Securities, joined existing investors, including 8VC, Viking Global Investo... |
| 04.01.2023 | Mantra Bio Raises $9M in Series A-2 Financing | SAN FRANCISCO, CA, Mantra Bio announced it has raised $9 million in a Series A-2 financing. >> Click here for more funding data on Mantra Bio >> To export Mantra Bio funding data to PDF and Excel, click here Mantra Bio an... |
| 29.07.2020 | Mantra Bio : Announces $25 Million Series A Financing to Develop Next Generation Targeted Therapeutics Based on Platform for Engineering Targeted Exosome Vehicles | SAN FRANCISCO, July 29, 2020 /PRNewswire/ -- Mantra Bio today announced it has raised $25 million in a Series A financing to advance development of next generation, precision therapeutics based on its proprietary platform for engineering Ta... |
| 23.04.2018 | 8VC has closed its second early-stage fund, seemingly with an eye on logistics and biotech | 8VC, the early-stage, San Francisco-based venture firm founded in 2015 by serial entrepreneur Joe Lonsdale and four other general partners, has closed it second early-stage venture fund with $640 million in commitments, says one of its inve... |
| - | Mantra Bio | “Mantra Bio | We harness exosomes to deliver safe, highly targeted medicines.” |